Rebalancing the immune system.
Resolving inflammation.
As a preclinical stage biotech company, IMD Pharma develops novel chemical modalities based on phosphorus dendrimer platforms to treat chronically unbalanced immune systems.
Unmet medical needs
The immune system of patients suffering from Chronic Inflammatory Diseases (5-7% of the world’s population) produces more pro-inflammatory signals than regulatory (pro-resolutive) signals.
Despite the need to rebalance patients’ dysregulated immune systems, the therapeutic response is immunosuppression, causing treatment failure in up to 40% of cases.
Meet IMD-Pharma’s technology
We conceive and develop groundbreaking molecules with unprecedented mode of action, capable of rebalancing dysregulated immune systems by reducing the production of pro-inflammatory signals and promoting the production of anti-inflammatory (pro-resolutive) signals.
Meet IMD-Pharma’s technology
We conceive and develop groundbreaking molecules with unprecedented mode of action, capable of rebalancing dysregulated immune systems by reducing the production of pro-inflammatory signals and promoting the production of anti-inflammatory (pro-resolutive) signals.
Our ambition
Our pioneering work, grounded in innovative research and based on bold ideas, has the potential to accelerate transformational innovation and revolutionize the treatment of chronic inflammatory diseases and improve the quality of life of millions of patients around the world.
Pipeline
IMD-026
Therapeutic domain: rheumatoid arthritis/VEXAS syndrome
Discovery
Pre-clinical
Phase 1
Phase 2
Pre-clinical
IMD-006/IMD-026
Therapeutic domain: skin inflammation
Discovery
Pre-clinical
Phase 1
Phase 2
Pre-clinical
IMD-036
Undisclosed therapeutic domain
Discovery
Pre-clinical
Phase 1
Phase 2
Discovery
Let’s get in touch
Cédric-Olivier Turrin
+33 (0)6 48 16 85 39
IMD-Pharma S.A.S.
205 route de Narbonne (LCC-CNRS)
31077 Cedex 4
FRANCE
